source
- BridgeBio secures $1 billion in equity financing ahead of three upcoming drug launchesBridgeBio Pharma announced it has raised about $1 billion through a preferred equity transaction. The new capital will strengthen its balance sheet as the company prepares three potential drug lau…
- Angitia halts Phase 3 trial of AGA111 for degenerative disc diseaseAngitia Biopharmaceuticals announced that it has ended the Phase 3 study of its investigational therapy AGA111 in patients with degenerative disc disease who had undergone lumbar interbody fusion.…